About Us

The genesis of GT Medical Technologies and GammaTile  Therapy

 

For decades, clinicians have sought better treatment options for patients with brain tumors that would effectively target tumor cells while preserving eloquent tissue.

 

Driven to overcome the limitations of current treatments and raise the standard of care, a group of brain tumor specialists joined forces to address this critical, unmet need. Together with medical device experts, they developed GammaTile Therapy, Surgically Targeted Radiation Therapy (STaRT) for recurrent intracranial neoplasms.

®

TREATMENT CONSIDERATIONS 

GammaTile Therapy is intended to deliver radiation therapy in patients with newly diagnosed malignant brain tumors and recurrent brain tumors. The potential for, and symptoms of, adverse events related to radiation exposure vary depending on the radiosensitivity of the exposed tissue, the amount of radiation delivered, and the placement of GammaTile(s). Serious side effects related to GammaTile Therapy are rare, and may include radiation brain changes including necrosis. GammaTile Therapy should not be used for patients with known history of hypersensitivity to bovine-derived materials. Possible complications can occur with any neurosurgical procedure, including cerebrospinal fluid leaks, infection, delayed hemorrhage, and adhesion formation.

CONNECT WITH US
  • Twitter
  • LinkedIn
  • Facebook
  • YouTube

©2020 GT Medical Technologies, Inc. I All rights reserved | Privacy Policy | Terms of Use

IMPROVING THE LIVES OF PATIENTS WITH BRAIN TUMORS